Third-Trimester NT-proBNP for Pre-eclampsia Risk Prediction: A Comparison With sFlt-1/PlGF in a Population-Based Cohort
Authors' conclusion
Unselected NT-proBNP screening in the early third trimester has limited clinical value for predicting short- or long-term pre-eclampsia risk when compared to angiogenic biomarkers.
Study context
- Population
- Pregnant individuals from the Odense Child Cohort with NT-proBNP and sFlt-1/PlGF measured in the early third trimesterpregnant individuals sampled at a median gestational age of 29 weeks (Q1-Q3: 28.4–29.4)
- Participants
- 1,476 individuals
- Exposure
- Third-trimester NT-proBNP, alone and combined with the sFlt-1/PlGF ratio, for pre-eclampsia risk within and beyond 4 weeks of sampling
- Pre-eclampsia within 4 weeksn = 11
- Pre-eclampsia more than 4 weeks after samplingn = 110
- Outcome
- Pre-eclampsia per higher NT-proBNP level
- Follow-up
- Onset within 4 weeks and beyond 4 weeks after sampling
Methodological detailsOdense Child Cohort
- Odense Child Cohort
Main finding
As reported in the abstract
Higher NT-proBNPAdjusted odds ratio (95% CI)P value
Onset within 4 weeks
2.18(0.88–5.42)
P = 0.09Onset beyond 4 weeks
0.72(0.55–0.93)
P = 0.012Per higher NT-proBNP level, as printed
Observational data: associations, not effects.
Further findings
Predictive accuracy of NT-proBNP combined with sFlt-1/PlGF ratio vs sFlt-1/PlGF ratio alone · short- and long-term
- Combining NT-proBNP with the sFlt-1/PlGF ratio did not improve the predictive accuracy for short- or long-term pre-eclampsia risk compared to the sFlt-1/PlGF ratio alone
Original publication
Third-Trimester NT-proBNP for Pre-eclampsia Risk Prediction: A Comparison With sFlt-1/PlGF in a Population-Based Cohort. JACC Adv. Published 19 March 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →